India, the “Pharmacy of the World,” faces new U.S. trade challenges.
– Supplies 20% of all generic drugs globally. – Known as the “pharmacy of the world.” – Saves U.S. healthcare billions annually.
– U.S. sources nearly half its generics from India. – Indian generics dominate prescriptions for diabetes, anxiety, depression, cancer. – Saved $219B in 2022 alone.
Potential duties could undermine India’s position. – 31% of India’s pharma exports go to the U.S. – Policymakers fear impact on global affordable healthcare.
Global generic market = $614B by 2030. – India must use pharma strength in talks. – Position generics as a global public good.
– High drug prices in the U.S. – Pressure on India’s IP regime. – Push for patent exclusivity + data protection.
Safeguard TRIPS flexibilities. Resist Big Pharma monopoly pressure. Offer affordable generics post-patent expiry.
– Move beyond transactional deals. – Leverage negotiating capital with patent laws. – Promote joint ventures with U.S. & EU.
New markets: West Asia, Africa, South America, ASEAN. Focus: Technology transfer, biotech, innovation partnerships.
India must champion public health as a global good. Expand role as key supplier of affordable essential medicines. Secure industry, protect health, strengthen leadership.